Status:
RECRUITING
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
Lead Sponsor:
Mostafa Bahaa
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD i...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Both male and female will be
- Mild and moderate UC patients diagnosed and confirmed by endoscope
Exclusion
- Breast feeding
- Significant liver and kidney function abnormalities
- Colorectal cancer patients
- Patients with severe UC
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and / or drugs
- Known allergy to the dapagliflozin
Key Trial Info
Start Date :
August 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 20 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05986136
Start Date
August 20 2023
End Date
July 20 2028
Last Update
January 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Mansoura University
Al Mansurah, Egypt, 7650001